Johnson & Johnson Steps Up Medical Device Investment In China
This article was originally published in PharmAsia News
Executive SummaryJohnson & Johnson, known in China for its personal care and infant products, has of late stepped up efforts in its medical device business. Now the firm's second largest portfolio-with sales overtaking drugs and consumables for the past five consecutive years-medical device sales and profit have surpassed 36 percent growth annually. The firm also plans to acquire local companies in the sector to rapidly penetrate into the medium- and low-end medical device business, widely regarded as the first segment to benefit from China's health care reform. Johnson & Johnson is in the process of buying domestic firm DaBao Daily Chemicals; if successful, the 2.3 billion yuan deal will be J&J's biggest acquisition in China. (Click here for more - Chinese language)
You may also be interested in...
Hiring travails, inspection pre-announcement, lack of translators highlighted in congressional hearing on FDA foreign inspections.
The court included its decision on Amarin’s ’s petition for a writ of certiorari among the single-line denials of nearly 200 appeals to consider decisions in civil litigation and convictions in criminal cases. However, Amarin still eyes curbing competition from omega-3 supplements.